Both systems have proven (proteasome) or promise (HtrA/DegP) to be valuable targets for novel therapeutic drugs and antibiotics. The analyses of numerous crystal structures of the proteasome and the HtrA/DegP protein families complexed with ligands in conjunction with functional studies have provided a sound basis of structure-based design and development of many novel chemical entities as potential clinical candidates.
Clausen, T., Kaiser, M., Huber, R. and Ehrmann, M. (2011). HTRA proteases: regulated proteolysis in protein quality control. Nature Reviews Molecular Cell Biology 12,152-162.
Gräwert, M. A., Gallastegui, N., Stein, M., Schmidt, B., Kloetzel, P. M., Huber, R. and Groll, M. (2011). Elucidation of the α-keto-aldehyde binding mechanism: A lead structure motif for proteasome inhibition. Angewandte Chemie Int. Ed. 50, 542-544.